Reveal a new mechanism for EGFR carcinogenic

Researchers from the University of Texas Southwestern Medical Center found that cell division protein provides a signal under normal circumstances, when it is overactive recycling process will destroy the body's normal cells (cellular recycling), and promote the growth of cancer chemoresistance. Epidermal growth factor receptor (EGFR) expression of abnormally high levels in many types of cancer cells surface. Since this new research center, research director bite, Howard Hughes Medical Institute (HHMI) researcher Dr. Beth Levine reveals led by University of Texas Southwestern Medical Center, EGFR by binding to normal cells turn proteins Beclin of a recycling process, Close the autophagy process. Cells typically recycled unnecessary element by autophagy. The researchers also found that, EGFR inactivation of autophagy leads to non-small cell lung transplantation in vivo tumor growth in mice more quickly and resistance to chemotherapy.

"This type of cell surface receptors directly with Beclin 1 interaction and close autophagy, the discovery of this fact so that we have a basic understanding of certain oncogenes may be how cancer. Our results show that inactivation of autophagy may is in the process of lung cancer a crucial factor, "said Dr. Levine.

In an earlier study, Dr. Levine laboratory identified beclin 1 is confirmed to play the first mammalian gene function in autophagy. This gene defects may not only cause cancer, but also to promote aging, cause neurodegenerative diseases and infectious diseases.

Although the relationship between EGFR and cancer cell growth signal is applied between the long been known, and there are several drugs EGFR inhibitors have been listed for the fight against cancer, but the exact mechanism of this process remains a puzzle. The latest studies reveal Beclin 1 is an important way, EGFR possible through it makes the body's anticancer abnormal autophagy machinery to promote tumor growth.

A second new study found that chemotherapy resistance. There are a number of ongoing clinical trials, is for the use of autophagy inhibitors to overcome resistance to chemotherapy in many tumor formation test. Unexpectedly, Levine 'Dr. study found the opposite result: autophagy inhibition may actually make certain cancer chemotherapy in patients with mutations in the outcome worse. The researchers demonstrated that autophagy reduced autophagy in cancer cells compared to normal cell growth faster, more resistant to chemotherapy. Dr. Levine noted that these findings may be applicable to many different types of cancer, especially those dependent on Mouse Insulin-like growth factor 1 ELISA Kit http://www.cusabio.com/ELISA_Kit-84017/ to achieve rapid growth of cancer.

According to the study author Dr. John Minna said, about 10 percent of lung cancer patients with EGFR mutations. Especially for these patients, the study found that for the development of personalized targeted therapy may have important significance.

Dr. Minna said: "EGFR protein for the treatment of lung cancer is our most important target - especially those tumors in patients with certain EGFR mutations we have some oral drugs gained significantly in this subset of patients. the clinical benefit and improve their survival, but even these treatments will eventually be successful in patients resistant to treatment. "

"For two reasons, these new findings have important significance: First, they provide insights on how to EGFR-targeting therapeutic extended to a larger group of patients with lung cancer, including those that do not have mutations in the tumor patient population. second, they provide a new way to overcome the resistance of EGFR targeted therapy. "